Innova Captab Limited's Board of Directors, at its meeting held on 07 May 2026, approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors, B S R & Co. LLP (Firm Registration No. 101248W/W-100022), issued an unmodified opinion on both sets of financial results. The board meeting commenced at 02:30 P.M. (IST) and concluded at 03:32 P.M. (IST).

Consolidated Financial Performance

The group — comprising Innova Captab Limited (Holding Company), Univentis Medicare Limited (Wholly-owned Subsidiary), Sharon Bio-Medicine Limited (Step-Down Subsidiary), and Univentis Foundation (Subsidiary) — reported a significant improvement in consolidated revenues for FY26. The following table summarises the key consolidated financial metrics:

On a consolidated basis, total income for FY26 stood at ₹16,374.38 million compared to ₹12,557.21 million in FY25. Cost of materials consumed for the full year was ₹10,054.63 million, while employee benefits expense stood at ₹1,672.04 million. Finance costs rose to ₹168.98 million in FY26 from ₹24.05 million in FY25, and depreciation and amortisation expense increased to ₹451.79 million from ₹247.79 million. The group's basic and diluted earnings per share for FY26 stood at ₹24.63, compared to ₹22.41 in FY25.

EBITDA and Profitability Highlights

The company's press release provides a summary of key performance indicators in crores, highlighting EBITDA trends across periods. Notably, Q4 FY26 EBITDA stood at ₹66.7 crores versus ₹51.1 crores in Q4 FY25, with EBITDA margin at 14.9% compared to 16.2% in the prior-year quarter. The table below presents the financial summary as reported:

For Q4 FY26, revenue from operations registered strong growth of 42.3% to ₹447.8 crores versus ₹314.7 crores in Q4 FY25, while EBITDA grew 30.5% to ₹66.7 crores. EBITDA margin for the quarter stood at 14.9%, and PAT for the quarter was ₹38.1 crores, registering growth of 28.8% with a PAT margin of 8.5%. For the full year FY26, revenue from operations cumulated to ₹1,630.0 crores versus ₹1,243.7 crores in FY25, clocking growth of 31.1%. EBITDA for FY26 stood at ₹250.3 crores versus ₹198.2 crores in FY25, growing at 26.3%, with an EBITDA margin of 15.4%. Full-year PAT came in at ₹140.9 crores with a PAT margin of 8.6%.

Standalone Financial Performance

On a standalone basis, Innova Captab reported revenue from operations of ₹12,988.14 million for FY26, up from ₹9,580.61 million in FY25. The key standalone financial metrics are presented below:

Standalone cost of materials consumed for FY26 was ₹9,013.73 million, while employee benefits expense stood at ₹1,110.90 million. Finance costs increased to ₹154.21 million from ₹21.68 million in FY25, and depreciation and amortisation expense rose to ₹373.67 million from ₹170.15 million. Standalone basic and diluted earnings per share for FY26 stood at ₹14.63, compared to ₹15.63 in FY25.

Balance Sheet and Cash Flow Highlights

On a consolidated basis, total assets as at 31 March 2026 stood at ₹18,373.79 million, compared to ₹15,804.07 million as at 31 March 2025. Total equity increased to ₹10,907.92 million from ₹9,594.17 million. Consolidated net cash generated from operating activities for FY26 was ₹1,165.15 million, compared to ₹638.44 million in FY25. Cash and cash equivalents at the end of FY26 stood at ₹31.99 million on a consolidated basis, against ₹155.19 million at the end of FY25.

On a standalone basis, total assets as at 31 March 2026 were ₹15,470.85 million versus ₹13,651.44 million as at 31 March 2025. Standalone total equity stood at ₹8,866.54 million, up from ₹8,129.65 million. Standalone net cash generated from operating activities was ₹341.06 million in FY26, compared to ₹198.01 million in FY25, while cash and cash equivalents at year-end stood at ₹13.65 million against ₹153.07 million in FY25.

Management Commentary and Operational Highlights

Commenting on the company's performance, Mr. Vinay Lohariwala, Managing Director, Innova Captab Limited, said: "Innova Captab Ltd has a strong performance with YoY revenue growth of 42% in Q4 FY26 and has delivered its highest-ever annual revenue with a growth of 31% in FY26. This strong performance underscores disciplined execution across our operations. This milestone performance was driven by sustained momentum across our CDMO and branded generics businesses, supported by an expanding product portfolio and increasing customer engagement. Operational excellence remains central, backed by state-of-the-art manufacturing infrastructure and stringent quality processes. During the year, we received key certifications including UK-MHRA for our Baddi facility and PIC/S for our Jammu blocks, enhancing our presence in regulated markets. The Jammu facility has completed its first full year of operations and is ramping up well, with multiple marquee clients successfully completing regulatory and customer audits. With multiple growth levers in place, we remain confident in sustaining momentum and delivering long-term value to our stakeholders."

The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies including WHO-GMP, EU-GMP, UK-MHRA, and PIC/S. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides pharmaceutical products to over 350 clients in India and key international markets.

Dividend and Other Key Developments

The Board of Directors had approved an interim dividend of ₹2 per equity share (face value ₹10 per share) at its meeting held on 23 January 2026. The company operates under a single reportable segment — Drugs and pharmaceutical products — as per Ind-AS 108. Additionally, the Board approved an amendment to the company's policy on dealing with Related Party Transactions at the 07 May 2026 meeting, in compliance with applicable provisions of the Companies Act, 2013 and the Listing Regulations. The equity share capital remained unchanged at ₹572.25 million across all reported periods.

On April 3, 2026, innova captab Limited submitted a regulatory declaration to BSE Limited and the National Stock Exchange of India Limited, confirming that its promoters and Persons Acting in Concert (PACs) have not created any encumbrance on their equity shareholding during the financial year ended March 31, 2026. The declaration was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and was digitally signed by promoter Vinay Lohariwala on behalf of all promoters and PACs.

Regulatory Declaration Details

Vinay Lohariwala, acting as promoter of Innova Captab Limited, confirmed that neither he nor any other promoter or PAC has made any encumbrance — directly or indirectly — on the equity shares held by them during the financial year ended March 31, 2026. The declaration was addressed to BSE Limited, the National Stock Exchange of India Limited, and the Audit Committee of Innova Captab Limited. The filing was digitally signed on April 3, 2026, at 12:58:09 IST.

Promoters and Persons Acting in Concert

The declaration was accompanied by a list of promoters and PACs holding shares in the company. The following individuals are identified in the filing:

Filing Details

The declaration was submitted from the company's registered address at Plot No. 320, Industrial Area, Phase-1, Panchkula, Pin-134113, Haryana, India. The filing was made to both major Indian stock exchanges in compliance with the applicable SEBI regulatory framework governing substantial acquisition of shares and takeovers.